Amcyte Pharma, Inc.

Warning LetterOpen

United StatesIssued Jan 3, 2022Center for Drug Evaluation and Research | CDER

View Letter

Source: FDA, published letter. FDA published this warning letter; View Letter opens FDA's copy.

Violations0

Issue DateJan 3, 2022

Product TypeDrugs

StatusOpen

Letter Details

Firm: Amcyte Pharma, Inc.
Location: United States
FEI Number: N/A
Country: United States
Issue Date: January 03, 2022
Issuing Office: Center for Drug Evaluation and Research | CDER
Product Type: Drugs
Status: Open

Summary

Based on limited metadata available, the FDA issued a warning letter to Amcyte Pharma, Inc., a pharmaceutical drug manufacturer, on January 3, 2022. Without access to the full letter text or detailed subject information, the specific nature of the violations cannot be determined with certainty. The letter falls under FDA oversight of drug products, though the specific issuing office and violation details remain unavailable in this metadata summary.

Amcyte Pharma, Inc. FDA Warning Letter, January 3, 2022